In one preclinical study using mouse tumor models, two mechanisms were shown to promote robust tumor rejection: tumor Treg depletion and effector T cell agonism by anti-CD137 mAbs, which, however, are competitive and dependent on antibody isotype and FcγR availability. Here, FCGR2A is linked to neoplasm.